Document:

Exhibit 10.1

 

 

 

 

 

 

COMMON STOCK PURCHASE AGREEMENT

 

by and between

 

Interleukin Genetics, Inc.

 

and

 

The Purchasers Identified on Schedule
I Hereto

 

 

 

May 17, 2013

 

 

 

    	 

    	 

    
 

	 	 	Page
	 	 	 
	1.	PURCHASE AND SALE	1
	 	(a)	Authorization of Shares	1
	 	(b)	Purchase of Shares and Warrant	1
	2.	CLOSINGS	1
	 	(a)	Initial Closing	1
	 	(b)	Subsequent Closings	2
	 	(c)	Form of Payment	3
	 	(d)	Conditions to the Purchaser’s Obligation to Purchase on the Initial Closing Date	3
	 	(e)	Conditions to the Purchaser’s Obligation to Purchase on each Subsequent Closing Date	5
	 	(f)	Conditions to the Company’s Obligation to Issue and Sell on the Initial Closing Date	6
	 	(g)	Conditions to the Company’s Obligation to Issue and Sell on each Subsequent Closing Date	7
	3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	8
	 	(a)	Organization and Qualification	8
	 	(b)	Subsidiaries	8
	 	(c)	Authorization; Enforcement; Validity	8
	 	(d)	Capitalization	9
	 	(e)	Issuance of Shares	9
	 	(f)	No Conflicts	10
	 	(g)	No Violation or Default	10
	 	(h)	SEC Documents	10
	 	(i)	Financial Statements	11
	 	(j)	No Material Adverse Change	11
	 	(k)	Independent Accountants	11
	 	(l)	Title to Intellectual Property	12

 

 

    	i

    	 

    

  

	 	 	 	Page
	 	 	 	 
	 	(m)	Licenses and Permits; Compliance with Law	12
	 	(n)	Insurance	13
	 	(o)	Related Party Transactions	13
	 	(p)	Environmental Matters	13
	 	(q)	Tax Matters	13
	 	(r)	Employees	14
	 	(s)	Internal Control over Financial Reporting	14
	 	(t)	Disclosure Controls and Procedures	14
	 	(u)	Sarbanes-Oxley Compliance	14
	 	(v)	Absence of Litigation	15
	 	(w)	Investment Company Act	15
	 	(x)	No Market Manipulation	15
	 	(y)	Foreign Corrupt Practices	15
	 	(z)	Brokers	15
	 	(aa)	Regulation	15
	4.	PURCHASERS’ REPRESENTATIONS AND WARRANTIES	16
	 	(a)	Transfer or Resale	16
	 	(b)	Investment Purpose	16
	 	(c)	General Solicitation	16
	 	(d)	Information	16
	 	(e)	Reliance on Exemptions	16
	 	(f)	No Governmental Review	17
	 	(g)	Authorization; Enforcement; Validity	17
	 	(h)	No Conflicts	17
	5.	RESTRICTIONS ON TRANSFER	17
	 	(a)	Resales	17
	 	(b)	Rule 144	18
	 	(c)	Legends	18

 

    	ii

    	 

    

 

	 	 	 	Page
	 	 	 	 
	 	(d)	Legend Removal	19
	6.	BOARD COMPOSITION	19
	 	(a)	Board Composition Following the Initial Closing; Appointment of Director Designees	19
	 	(b)	Nominations of Director Designees	19
	 	(c)	Successor Director Designees	20
	 	(d)	Indemnification Agreements	20
	 	(e)	Committees of the Board of Directors	20
	 	(f)	Amendment of this Section 6	20
	 	(g)	Board Observer Rights	20
	7.	OTHER AGREEMENTS AND COVENANTS	21
	 	(a)	Shareholder Meeting	21
	 	(b)	National Market Listing	21
	 	(c)	Option Pool	21
	 	(d)	Use of Proceeds	22
	 	(e)	Certificate of Elimination	22
	 	(f)	Form D; Blue Sky Filings	22
	 	(g)	Reservation of Shares	22
	 	(h)	Exchange Act Filings	22
	 	(i)	Integration	22
	 	(j)	Expenses	23
	 	(k)	Purchaser/Director Designee Exchange Act Filings	23
	8.	PUBLIC STATEMENTS	23
	9.	MISCELLANEOUS	23
	 	(a)	Governing Law	23
	 	(b)	Entire Agreement	24
	 	(c)	Amendments and Waivers	24
	 	(d)	Notices	24

 

    	iii

    	 

    

  

	 	 	 	Page
	 	 	 	 
	 	(e)	No Strict Construction	25
	 	(f)	Further Assurances	25
	 	(g)	Severability	25
	 	(h)	Successors and Assigns	25
	 	(i)	Survival	25
	 	(j)	No Third-Party Beneficiaries	25
	 	(k)	Replacement of Securities	25
	 	(l)	Independent Nature of Purchasers’ Obligations and Rights	26
	 	(m)	Business Day	26
	 	(n)	Headings	26
	 	(o)	Execution	26

 

SCHEDULES

Schedule I – List of Purchasers

 

EXHIBITS

Exhibit A – Form of Warrant

 

Exhibit B – Director Indemnity Agreement

 

Exhibit C – Registration Rights Agreement

 

 

    	iv

    	 

    

 

COMMON
STOCK PURCHASE AGREEMENT

 

This Common Stock Purchase Agreement (this
“Agreement”) dated as of May 17, 2013 is made by and between Interleukin Genetics, Inc., a Delaware corporation,
(the “Company”), and each purchaser identified on Schedule I hereto (each a “Purchaser”),
and together, the “Purchasers”). 

 

RECITALS

 

In accordance with the terms and conditions
of this Agreement and pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities
Act”), the Company has agreed to issue and sell, and each Purchaser has agreed, severally and not jointly, to purchase
from time to time a number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”),
and a warrant to purchase a number of shares of Common Stock (the “Warrant”, and together with all such warrants
being issued to Purchasers under this Agreement, the “Warrants”), each as set forth opposite such Purchaser’s
name on Schedule I to this Agreement.

 

NOW THEREFORE, in consideration of the promises
and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each Purchaser hereby agree as follows:

 

1.                 
PURCHASE AND SALE

 

(a)         
Authorization of Shares. The Company has authorized (i) the sale and issuance to the Purchasers of the shares
of Common Stock, (ii) the sale and issuance to the Purchasers of the Warrants, and (iii) the issuance of shares of Common
Stock to be issued upon exercise of the Warrants (the “Warrant Shares”).

 

(b)        
Purchase of Shares and Warrant. At each Closing, the Company shall issue and sell to each Purchaser, and each Purchaser
shall, severally and not jointly, purchase from the Company, upon the terms and subject to the conditions set forth in this Agreement,
(i) the number of shares of Common Stock set forth opposite such Purchaser’s name on Schedule I to this Agreement
(the “Shares”) and (ii) a Warrant to purchase the number of shares of Common Stock set forth opposite such Purchaser’s
name on Schedule I to this Agreement, for an aggregate purchase price as set forth opposite such Purchaser’s name
on Schedule I to this Agreement (the “Purchase Price”), based on a purchase price per Share of $0.2745
(the “Per Share Purchase Price”).

 

2.                 
CLOSINGS

 

(a)         
Initial Closing. The date and time of the initial Closing of the purchase and sale of the Shares and the Warrants
(the “Initial Closing”) shall occur on May 17, 2013 at 12:00 p.m. Boston time, at the offices of Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts, 02111 (subject to the satisfaction or waiver
of the conditions set forth in Subsections (d) and (f) of this Section 2), or at such other location, date and time as may be agreed
upon between the Company and the Purchasers (the “Initial Closing Date”).

 

    	 

    	 

    

 

(b)        
Subsequent Closings.

 

		(i)	Each Purchaser at the Initial Closing shall have the option, exercisable in its sole and exclusive discretion at any time and
from time to time following the date of the Shareholder Approval of Increase in Authorized Shares (as defined in Section 7(a) below)
and on or before June 30, 2014 (the “Expiration Date”), to purchase (and upon receipt of a Demand Notice (as
defined below) from a Purchaser, the Company must sell) at one or more subsequent Closings on or before the Expiration Date (each
such Closing, a “Subsequent Closing”), on the same terms and conditions as those contained in this Agreement,
additional Shares and additional Warrants in an aggregate amount not to exceed the number of Shares and the number of Warrant Shares
set forth opposite such Purchaser’s name under the heading “Subsequent Closings” on Schedule I hereto.
Any Purchaser electing to purchase additional Shares and an additional Warrant at a Subsequent Closing shall provide written notice
thereof to the Company, stating the number of additional Shares to be purchased and the number of Warrant Shares to be subject
to the accompanying Warrant (which shall equal seventy-five percent (75%) of the number of additional Shares to be purchased at
such Subsequent Closing), duly executed by such Purchaser and delivered to the Company in accordance with Section 9(d) (the “Demand
Notice”). Following its delivery of a Demand Notice to the Company (and subject to the satisfaction or waiver of the
conditions set forth in Subsections (e) and (g) of this Section 2), such Purchaser shall purchase from the Company, and the Company
shall issue and sell to such Purchaser, at the Per Share Purchase Price, the additional Shares and Warrant as set forth in the
Demand Notice. Each Subsequent Closing shall occur at such location, date and time as may be agreed upon between the Company and
the Purchaser exercising the Purchaser Demand (each, a “Subsequent Closing Date”). The Initial Closing and each
Subsequent Closing may also be referred to in this Agreement as a “Closing,” and the Initial Closing Date and
each Subsequent Closing Date may also be referred to in this Agreement as a “Closing Date.”

 

		(ii)	In the event that a Purchaser does not purchase any portion of the additional Shares and Warrant Shares set forth opposite
such Purchaser’s name under the heading “Subsequent Closings” on Schedule I hereto on or before the Expiration
Date (a “Non-Participating Purchaser”), then the Company shall provide written notice of such non-participation
to each participating Purchaser (each a “Participating Purchaser”). Within thirty (30) days following the Company’s
delivery of such notice, each Participating Purchaser shall have the right, but not the obligation, to purchase its pro rata portion
of any additional Shares and Warrant Shares allocated to a Non-Participating Purchaser. In addition, each Participating Purchaser
shall have the right, but not the obligation, to oversubscription such that if any other Participating Purchaser fails to purchase
its full pro rata portion of a Non-Participating Purchaser’s additional Shares and Warrant Shares, the other Participating
Purchasers shall, among them, have the right to purchase up to the balance of the additional Shares and Warrant Shares not so purchased.
If, as a result thereof, such oversubscriptions exceed the total number of additional Shares and Warrant Shares available in respect
of such oversubscription right, the oversubscribing Participating Purchasers shall be cut back with respect to their oversubscriptions
in accordance with their respective pro rata portion. For purposes of this Section 2(b)(ii), a Participating Purchaser’s
pro rata portion is equal to the quotient obtained by dividing the total number of Shares purchased by such Participating Purchaser
pursuant to this Agreement by the total number of Shares purchased by all Participating Purchasers pursuant to this Agreement.

 

    	2

    	 

    

 

(c)         
Form of Payment. On the applicable Closing Date, each Purchaser shall pay the Company the Purchase Price for the
Shares and the Warrant to be issued and sold to such Purchaser on such Closing Date, by wire transfer of immediately available
funds in accordance with the Company’s written wire instructions previously provided to the Purchasers, and the Company shall
deliver to each Purchaser the original certificate or certificates representing the Shares and the original Warrant, duly executed
on behalf of the Company and registered in the name of such Purchaser.

 

(d)        
Conditions to the Purchaser’s Obligation to Purchase on the Initial Closing Date. Each Purchaser’s obligation
to purchase the Shares and the Warrant at the Initial Closing shall be subject to the satisfaction, on or before the Initial Closing
Date, of each of the following conditions, provided that these conditions are for the Purchaser’s sole benefit and may be
waived by such Purchaser at any time in its sole discretion:

 

		(i)	receipt of a copy of this Agreement executed by the Company;

 

		(ii)	Pyxis Innovations Inc. (the “Series A-1 Stockholder”) shall have converted all outstanding shares of Series
A-1 convertible preferred stock (the “Series A-1 Preferred Stock”) held by it into 28,160,200 shares of Common
Stock in accordance with the terms of the Certificate of Designations, Preferences and Rights of Series A-1 Preferred Stock and
Series B Preferred Stock (the “Certificate of Designation”) (the “Series A-1 Conversion”);

 

		(iii)	Delta Dental Plan of Michigan, Inc. (the “Series B Stockholder”) shall have converted all outstanding shares
of Series B convertible preferred stock (the “Series B Preferred Stock”) held by it into 10,928,961 shares of
Common Stock in accordance with the terms of the Certificate of Designation (the “Series B Conversion”, and
together with the Series A-1 Conversion, the “Preferred Stock Conversion”);

 

		(iv)	the Series A-1 Stockholder shall have converted an aggregate of $14,316,255 in principal amount of outstanding convertible
debt (the “Debt”) issued to the Company pursuant to the Amended and Restated Note Purchase Agreement, dated
March 11, 2009, as amended (the “Note Purchase Agreement”), and as evidenced by the Promissory Notes issued
thereunder (the “Notes”), into 2,521,222 shares of Common Stock in accordance with the terms thereof (the “Debt
Conversion”);

 

    	3

    	 

    

  

		(v)	evidence of irrevocable instructions from the Company to the transfer agent for the Common Stock with respect to the issuance
and delivery of one or more certificates representing the Shares;

 

		(vi)	receipt of the Warrant in the form attached as Exhibit A;

 

		(vii)	(A) all actions required by the Board of Directors of the Company (the “Board”) to effect the provisions
of Section 6 of this Agreement with respect to the composition of the Board following the Initial Closing, including the appointment
of the two Purchaser Designees (as defined below), shall have been taken; (B)  the Company shall have taken all necessary
action for such Purchaser Designees to be fully covered by the Company’s directors’ and officers’ liability insurance
in an amount no less than all other directors; and (C) the Company shall have entered into a director indemnity agreement
with each of the Purchaser Designees in substantially the form attached as Exhibit B;

 

		(viii)	all consents, approvals and waivers required for the consummation of the transactions contemplated hereby shall have been obtained,
including the waiver of all anti-dilution and other rights and all other such consents, approvals and waivers required of the Series
A-1 Stockholder (with respect to the Series A-1 Preferred Stock and the Debt) and the Series B Stockholder (with respect to the
Series B Preferred Stock) (the “Preferred Stockholder Approvals”);

 

		(ix)	the Company shall have delivered to the Purchasers a Compliance Certificate, executed by the Chief Executive Officer of the
Company, dated as of the Initial Closing Date, to the effect that the conditions specified in subsections (vii), (viii), (xi),
and (xii) of this Section 2(d) have been satisfied;

 

		(x)	the Company shall have delivered to the Purchasers a certificate of its Secretary certifying as to (A) the resolutions
of the Board approving this Agreement and the transactions contemplated hereby, including the actions required by the Company pursuant
to this Section 2(d); and (B) good standing certificates (including tax good standing) with respect to the Company from
the applicable authority(ies) in Delaware and any other jurisdiction in which the Company is qualified to do business dated a recent
date before the Initial Closing;

 

    	4

    	 

    

 

		(xi)	the representations and warranties of the Company in this Agreement shall be true, correct and complete as of the Initial Closing
Date (except for representations and warranties that speak as of a specific date, which shall be true, correct and complete as
of such date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Initial
Closing;

 

		(xii)	no temporary restraining order, preliminary or permanent injunction or other order or decree, and no other legal restraint
or prohibition, shall exist which questions the validity of this Agreement or the right of the Company or any Purchaser, as the
case may be, to enter into this Agreement or prevents or could reasonably be expected to prevent the consummation of the transactions
contemplated by this Agreement, nor shall any litigation or court or administrative proceeding have been commenced or threatened
with respect to the foregoing;

 

		(xiii)	the Company shall have executed and delivered the Registration Rights Agreement in substantially the form attached as Exhibit C
(the “Registration Rights Agreement”);

 

		(xiv)	delivery of a legal opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, Company counsel, in form and substance reasonably
satisfactory to the Purchasers;

 

		(xv)	evidence satisfactory to the Purchasers that the Note Purchase Agreement, has been terminated and the Notes have been converted;

 

		(xvi)	evidence satisfactory to the Purchasers that holders of the number of shares required to approve the Shareholder Approval of
Increase in Authorized Shares (as defined below) (other than the Purchasers) have agreed to vote such shares in favor thereof;
and

 

		(xvii)	receipt of such other information, certificates and documents as the Purchasers may reasonably request.

 

(e)         
Conditions to the Purchaser’s Obligation to Purchase on each Subsequent Closing Date. Each Purchaser’s
obligation to purchase the Shares and the Warrant at each Subsequent Closing shall be subject to the satisfaction, on or before
such Subsequent Closing Date, of each of the following conditions, provided that these conditions are for the Purchaser’s
sole benefit and may be waived by such Purchaser at any time in its sole discretion:

 

		(i)	receipt of Shareholder Approval of Increase in Authorized Shares;

 

		(ii)	evidence of irrevocable instructions from the Company to the transfer agent for the Common Stock with respect to the issuance
and delivery of one or more certificates representing the Shares;

 

		(iii)	receipt of the Warrant in the form attached as Exhibit A;

 

    	5

    	 

    

  

		(iv)	the Company shall have delivered to the Purchasers a Compliance Certificate, executed by the Chief Executive Officer of the
Company, dated as of such Subsequent Closing Date, to the effect that the conditions specified in subsections (vi) and (vii)
of this Section 2(e) have been satisfied;

 

		(v)	the Company shall have delivered to the applicable Purchaser good standing certificates (including tax good standing) with
respect to the Company from the applicable authority(ies) in Delaware and any other jurisdiction in which the Company is qualified
to do business dated a recent date before such Subsequent Closing;

 

		(vi)	the representations and warranties of the Company in this Agreement shall be true, correct and complete as of the date of this
Agreement and as of such Subsequent Closing Date (except for representations and warranties that speak as of a specific date, which
shall be true, correct and complete as of such date) and the Company shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by
the Company at or prior to such Subsequent Closing; and

 

		(vii)	no temporary restraining order, preliminary or permanent injunction or other order or decree, and no other legal restraint
or prohibition, shall exist which questions the validity of this Agreement or prevents or could reasonably be expected to prevent
the consummation of the transactions contemplated by this Agreement, nor shall any litigation or court or administrative proceeding
have been commenced or threatened with respect to the foregoing.

 

(f)         
Conditions to the Company’s Obligation to Issue and Sell on the Initial Closing Date. The Company’s obligation
to issue and sell the Shares and the Warrant at the Initial Closing shall be subject to the satisfaction, on or before the Initial
Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit and
may be waived by the Company at any time in its sole discretion:

 

		(i)	receipt of a copy of this Agreement executed by each Purchaser;

 

		(ii)	receipt of the Purchase Price from each Purchaser;

 

		(iii)	the representations and warranties of each Purchaser in this Agreement shall be true, correct and complete as of the date of
this Agreement and as of the Initial Closing Date (except for representations and warranties that speak as of a specific date,
which shall be true, correct and complete as of such date) and each Purchaser shall have performed, satisfied and complied with
in all material respects the covenants, agreements and conditions of such Purchaser to be performed, satisfied or complied with
by it under this Agreement at or prior to the Initial Closing Date; and

 

    	6

    	 

    

  

		(iv)	no temporary restraining order, preliminary or permanent injunction or other order or decree, and no other legal restraint
or prohibition shall exist which questions the validity of this Agreement or the right of the Company or any Purchaser, as the
case may be, to enter into this Agreement or prevents or could reasonably be expected to prevent the consummation of the transactions
contemplated by this Agreement, nor shall any litigation or court or administrative proceeding have been commenced or threatened
with respect to the foregoing.

 

(g)        
Conditions to the Company’s Obligation to Issue and Sell on each Subsequent Closing Date. The Company’s
obligation to issue and sell the Shares and the Warrant at each Subsequent Closing shall be subject to the satisfaction, on or
before such Subsequent Closing Date, of each of the following conditions, provided that these conditions are for the Company’s
sole benefit and may be waived by the Company at any time in its sole discretion:

 

		(i)	receipt of Shareholder Approval of Increase in Authorized Shares;

 

		(ii)	receipt of the Purchase Price from each Purchaser;

 

		(iii)	the representations and warranties of each Purchaser in this Agreement shall be true, correct and complete as of the date of
this Agreement and as of such Subsequent Closing Date (except for representations and warranties that speak as of a specific date,
which shall be true, correct and complete as of such date) and each Purchaser shall have performed, satisfied and complied with
in all material respects the covenants, agreements and conditions of such Purchaser to be performed, satisfied or complied with
by it under this Agreement at or prior to such Subsequent Closing Date; and

 

		(iv)	no temporary restraining order, preliminary or permanent injunction or other order or decree, and no other legal restraint
or prohibition shall exist which questions the validity of this Agreement or prevents or could reasonably be expected to prevent
the consummation of the transactions contemplated by this Agreement, nor shall any litigation or court or administrative proceeding
have been commenced or threatened with respect to the foregoing.

 

    	7

    	 

    

 

3.                 
REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to each
Purchaser, subject to such exceptions as are set forth in the SEC Documents (as defined below) (other than (x) those sections of
the SEC Documents entitled or captioned “Risk Factors,” (y) any disclosure of risks included in any forward-looking
statements disclaimer or other statements that are similarly non-specific and are predictive or forward looking in nature and (z)
specific disclosures contained in those documents which are filed as exhibits to the SEC Documents), provided that the relevance
of such exceptions to the representations and warranties is reasonably apparent, as follows:

 

(a)         
Organization and Qualification. The Company is a corporation, duly organized, validly existing and in good standing
under the laws of the State of Delaware, and has the requisite corporate power and authority to own its properties and to carry
on its business as now being conducted and as described in the SEC Documents. Copies of the Company’s Certificate of Incorporation,
as amended (the “Charter”), and Amended and Restated Bylaws of the Company, as amended (the “Bylaws”),
and in each case, all amendments thereto, have been filed as exhibits to the Company’s SEC Documents and have not been further
modified, and except for the filing of the Certificate of Elimination (as defined below) and as otherwise may be required by the
transactions contemplated hereby, the Company has no present intention to modify the Charter and Bylaws. The Company is duly qualified
as a foreign corporation to do business, and is in good standing, in every jurisdiction in which its ownership of property or the
nature of the business conducted and proposed to be conducted by it makes such qualification necessary, except where the failure
to be so qualified or in good standing would not, individually or in the aggregate, have or reasonably be expected to result in
a material adverse effect on (i) the condition (financial or otherwise), prospects, earnings, assets, results of operations, business
or properties of the Company, whether or not arising from transactions in the ordinary course of business or (ii) the ability of
the Company to consummate the transactions contemplated by this Agreement (“Material Adverse Effect”).

 

(b)        
Subsidiaries. The Company has no subsidiaries.

 

(c)         
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and
perform its obligations under this Agreement, the Registration Rights Agreement and each of the other agreements entered into by
the parties hereto in connection with transactions contemplated by this Agreement (collectively, the “Transaction Documents”)
and to issue the Shares and the Warrants in accordance with the terms hereof and thereof. The execution and delivery of the Transaction
Documents by the Company and the consummation and performance by the Company of the transactions contemplated hereby and thereby,
including, without limitation, the issuance of the Shares, Warrants and the Warrant Shares (collectively, the “Securities”),
have been duly authorized by all requisite corporate action. The Transaction Documents have been duly executed and delivered by
the Company. The Transaction Documents constitute the valid and binding obligations of the Company enforceable against the Company
in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies.

 

    	8

    	 

    

 

(d)        
Capitalization. As of the date of this Agreement (and prior to the filing of the Certificate of Elimination), the
authorized capital stock of the Company consists of (i) 150,000,000 shares of Common Stock and (ii) 6,000,000 shares of preferred
stock, $0.001 par value per share, 5,000,000 of which have been designated as Series A-1 Preferred Stock and 500,000 of which have
been designated as Series B Preferred Stock. As of the date of this Agreement and prior to the Preferred Stock Conversion and the
Debt Conversion and prior to the issuance of the Shares and Warrants under this Agreement, (i) 36,814,488 shares of Common Stock
are issued and outstanding; (ii) 5,000,000 shares of Series A-1 Preferred Stock are issued and outstanding (which are convertible
into 28,160,200 shares of Common Stock); (iii) 500,000 shares of Series B Preferred Stock are issued and outstanding (which are
convertible into 10,928,961 shares of Common Stock); (iv) 2,435,500 shares of Common Stock are duly reserved for future issuance
pursuant to outstanding stock options; (v) 2,187,158 shares of Common Stock are duly reserved for future issuance pursuant to outstanding
warrants; (vi) 2,521,222 shares of Common Stock are duly reserved for future issuance pursuant to outstanding convertible debt;
(vii) 1,843,780 shares of Common Stock are duly reserved for future issuance pursuant to the Company’s stock plans;
and (viii)  699,376 shares of Common Stock are duly reserved for future issuance pursuant to the Company’s employee
stock purchase plan. All of the issued shares of capital stock of the Company have been duly and validly authorized and issued,
are fully paid and non-assessable, and have been issued in compliance with federal and state securities laws. Except as set forth
above, (i) no shares of the Company’s capital stock are subject to preemptive rights or any other similar rights or any liens
or encumbrances; (ii) there are no outstanding options, warrants, rights to subscribe to, calls or commitments relating to, or
securities or rights convertible into, any shares of capital stock of the Company, or contracts, commitments, understandings or
arrangements by which the Company is or may become bound to issue additional shares of capital stock of the Company or options,
warrants, rights to subscribe to, calls or commitments relating to, or securities or rights convertible into, any shares of capital
stock of the Company. The Company has no knowledge of any voting agreements, buy-sell agreements, option or right of first purchase
agreements or other agreements of any kind among any of the security holders of the Company relating to the securities of the Company
held by them. Other than pursuant to the Registration Rights Agreement, and except as set forth in (i) that certain Registration
Rights Agreement between the Company and the Series A-1 Stockholder dated March 5, 2003 and (ii) that certain Registration
Rights Agreement between the Company and the Series B Stockholder dated June 29, 2012, the Company has not granted any person the
right to require the Company to register any securities of the Company under the Securities Act, whether on a demand basis or in
connection with the registration of securities of the Company for its own account or for the account of any other person.

 

(e)         
Issuance of Shares. The Shares and the Warrant Shares have been duly and validly reserved for issuance (except for
Shares and Warrant Shares, the issuance of which is conditioned upon and subject to receipt of Shareholder Approval of Increase
in Authorized Shares). The Shares and the Warrant Shares are duly authorized (except for Shares and Warrant Shares, the issuance
of which is conditioned upon and subject to receipt of Shareholder Approval of Increase in Authorized Shares) and, upon issuance
in accordance with the terms hereof and the Warrants, will be (A) validly issued, fully paid and non-assessable and (B) free from
all taxes, liens and charges in the United States of America with respect to the issuance thereof, other than any liens or encumbrances
created by or imposed by the Purchaser, and not subject to preemptive, registration, right of first refusal or other similar rights
of stockholders of the Company. Subject to the Preferred Stockholder Approvals, and except for the filing of any notice prior or
subsequent to the Closing that may be required under applicable state and/or federal securities laws (or comparable laws of any
other jurisdiction), no authorization, consent, approval, license, exemption of or filing or registration with any court or governmental
department, commission, board, bureau, agency, instrumentality or other third party, is or will be necessary for, or in connection
with, the execution and delivery by the Company of this Agreement, for the offer, issue, sale, execution or delivery of the Shares
and Warrants, or for the performance by the Company of its obligations under this Agreement. The Company has reserved from its
duly authorized capital stock the Shares and the Warrant Shares.

 

    	9

    	 

    

 

(f)         
No Conflicts. Subject to the Preferred Stockholder Approvals, the execution, delivery and performance of the Transaction
Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby do not and will
not (i) result in a breach or violation of the Company’s Charter or Bylaws; (ii) conflict with, or constitute a default (or
an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, or incremental, additional or varied rights under, any agreement, indenture, or other
instrument, obligation or understanding to which the Company is a party; (iii) result in a violation of any statute, law, rule,
regulation, order, judgment or decree (including federal and state securities laws) applicable to the Company; or (iv) result in
the imposition of a mortgage, pledge, security interest, encumbrance, charge or other lien on any asset of the Company.

 

(g)        
No Violation or Default. The Company is not (i) in violation of its Charter or Bylaws; (ii) in default (or subject
to an event which with notice or lapse of time or both would become a default) under any agreement, indenture or instrument to
which the Company is a party; or (iii) in violation of any law, rule, regulation, order, judgment or decree applicable to the Company;
except for such violations or defaults, as described in clauses (ii) or (iii) of this sentence as would not, individually or in
the aggregate, have or result in a Material Adverse Effect.

 

(h)        
SEC Documents. The Company has filed all reports, schedules, forms, statements, exhibits (including certifications
of the Company’s principal executive and financial officers pursuant to Section 302 and 906 of Sarbanes-Oxley (as defined
below)) and other documents required to be filed by it with the U.S. Securities and Exchange Commission (“SEC”)
pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
since January 1, 2012 (all of the foregoing filed prior to or on the date hereof, or prior to the Closing Date, and all exhibits
included therein and financial statements and schedules thereto and documents incorporated by reference therein being referred
to in this Agreement as the “SEC Documents”). As of the date of filing of each such SEC Document, such SEC Document,
as it may have been subsequently amended by filings made by the Company with the SEC prior to the date hereof, complied in all
material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable
to such SEC Document. None of the SEC Documents, as of the date filed and as they may have been subsequently amended by filings
made by the Company with the SEC prior to the date hereof, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

 

    	10

    	 

    

 

(i)          
Financial Statements. The financial statements and the related notes thereto of the Company included or incorporated
by reference in the SEC Documents comply in all material respects with the applicable requirements of the Exchange Act and present
fairly and accurately in all material respects the financial position of the Company as of the dates indicated and the results
of operations and the changes in cash flows for the periods specified. Such financial statements have been prepared in conformity
with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout
the periods covered thereby, except as specifically stated therein, and the supporting schedules included or incorporated by reference
in the SEC Documents present fairly the information required to be stated therein. The Company does not have any material liability
or obligation of any nature, whether or not accrued, contingent or otherwise that would be required by GAAP to be disclosed on
a balance sheet of the Company or in the notes thereto. The Company has not created any entities or entered into any transactions
or created any liabilities or obligations of any nature, whether or not accrued, contingent or otherwise, for the purpose of avoiding
disclosure required by GAAP.

 

(j)          
No Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated
by reference in the SEC Documents, except as disclosed in the SEC Documents and as contemplated by this Agreement, (i) there
has not been any change in the capital stock (other than pursuant to the Company's stock plans pursuant to the Company's existing
employee stock purchase plan (any such issuances, whenever issued or granted, being collectively “Employee Equity Transactions”),
pursuant to the conversion or exercise of outstanding securities that are convertible into or exercisable for Common Stock, or
pursuant to publicly disclosed equity or debt financings) or long-term debt of the Company, or any dividend or distribution of
any kind declared, set aside for payment, paid or made by the Company on any class of capital stock; (ii) the Company has not entered
into any transaction or agreement that is material to the Company taken as a whole or incurred any liability or obligation, direct
or contingent, that is material to the Company and, except as contemplated by this agreement, has not made any material change
or amendment to a material contract or arrangement by which the Company or any of its assets or properties is bound or subject;
(iii) the Company has not sustained any material loss or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator
or governmental or regulatory authority; and (iv) there has not been the occurrence of any Material Adverse Effect.

 

(k)        
Independent Accountants. Grant Thornton LLP, who have certified certain financial statements of the Company, have
advised the Company that they are, and to the Company’s knowledge they are, independent registered public accountants with
respect to the Company as required by the Securities Act. Except as pre-approved in accordance with the requirements set forth
in Section 10A of the Exchange Act, to the Company’s knowledge, Grant Thornton LLP has not engaged in any “prohibited
activities” (as defined in Section 10A of the Exchange Act) on behalf of the Company.

 

    	11

    	 

    

 

(l)          
Title to Intellectual Property. The Company owns or possesses adequate rights to use all patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions,
know-how and all other intellectual property rights (including trade secrets and other unpatented or unpatentable proprietary or
confidential compounds, genes, information, systems or procedures) (collectively, the “Intellectual Property”),
used in or necessary for the conduct of the Company’s business as now, or as contemplated to be, conducted. Except as set
forth in the SEC Documents, (i) there are no rights of third parties to any such Intellectual Property except through licensing
or cross-licensing agreements; (ii) to the Company’s knowledge, there is no infringement by third parties of any Intellectual
Property to which the Company can assert a claim of infringement; (iii) there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others challenging the Company’s ownership of or licensing rights in or to
any such Intellectual Property; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others challenging the validity or scope of any such Intellectual Property, other than ordinary patent, trademark,
service mark and copyright prosecution disclosed in the SEC Documents; (v) there is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others that the Company infringes or otherwise violates any Intellectual
Property of others, and the Company is unaware of any reasonable basis for any such claim; (vi) the Company has not been and
will not be required to utilize any inventions, trade secrets or proprietary information of any of its employees made prior to
their employment by the Company; (vii) the Company has taken all steps required to perfect its ownership of and interest in
its Intellectual Property; and (viii) the Company has taken reasonable security measures to protect the secrecy, confidentiality
and value of all of its Intellectual Property.

 

(m)      
Licenses and Permits; Compliance with Law. The Company possesses all licenses, certificates, permits and other authorizations
issued by, and has made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities, that are necessary for the ownership or lease of its properties and assets or the conduct of its business as conducted
or as contemplated to be conducted. The Company has not received notice of any revocation or modification of any such license,
certificate, permit or authorization, or of any proceeding relating to any such revocation or modification, or has any reason to
believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. The Company has
complied in all material respects with and is not in default or violation in any material respect of, and is not, to the Company’s
knowledge, under investigation with respect to or has not been, to the knowledge of the Company, threatened to be charged with
or given notice of any violation of, any applicable federal, state, local or foreign law, statute, ordinance, license, rule, regulation,
policy or guideline, order, demand, writ, injunction, decree or judgment of any federal, state, local or foreign governmental or
regulatory authority. Except for statutory or regulatory restrictions of general application, no federal, state, local or foreign
governmental or regulatory authority has placed any material restriction on the business or properties of the Company.

 

    	12

    	 

    

 

(n)        
Insurance. The Company maintains insurance of the types and in the amounts that the Company reasonably believes are
adequate for its businesses and consistent with insurance coverage maintained by similar companies in similar businesses, including,
but not limited to, insurance covering real and personal property owned or leased by the Company against theft, damage, destruction,
acts of vandalism, insurance covering the acts and omissions of directors and officers, and insurance covering all other risks
customarily insured against by similarly situated companies, all of which insurance is in full force and effect. The Company has
not received any written notice that the Company will not be able to renew its existing insurance coverage as and when such coverage
expires.

 

(o)        
Related Party Transactions. None of the officers or directors of the Company and, to the knowledge of the Company,
none of the employees of the Company is presently a party to any transaction with the Company (other than for services as employees,
officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than (i) for payment of salary
or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) for
other employee benefits, including stock option agreements under any stock option plan of the Company.

 

(p)        
Environmental Matters. The Company is in compliance with all foreign, federal, state and local rules, laws and regulations
relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety
or the environment which are applicable to their businesses. To the Company’s knowledge, there has been no storage, generation,
transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other
hazardous substances by, due to, or caused by the Company (or, to the Company’s knowledge, any other entity for whose acts
or omissions the Company is or may be liable) upon any of the property now or previously owned or leased by the Company, or upon
any other property, in violation of any statute or any ordinance, rule, regulation, order, judgment, decree or permit or which
would, under any statute or any ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit,
give rise to any liability. There has been no disposal, discharge, emission or other release of any kind onto such property or
into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which
the Company has knowledge.

 

(q)        
Tax Matters. The Company (i) has timely filed all necessary federal, state, local and foreign income and franchise
tax returns or has requested extensions thereof, (ii) has paid all federal state, local and foreign taxes due and payable for which
it is liable, except for any such taxes currently being contested in good faith, and (iii) does not have any tax deficiency or
claims outstanding or assessed or, to the best of the Company’s knowledge, proposed against it. All material taxes and other
assessments and levies that the Company is required to withhold or to collect for payment have been duly withheld and collected
and paid to the proper government entity or third party when due. There are no tax liens or claims pending or, to the Company’s
knowledge, threatened against the Company or any of its respective assets or property. Except as set forth in the SEC Documents,
there are no outstanding tax sharing agreements or other such arrangements between the Company and any other Person.

 

    	13

    	 

    

 

(r)          
Employees. All current and former employees of the Company have executed and delivered a confidential information
and inventions assignment agreement (a “CIIA”) to the Company. All current and former consultants of the Company
that had access to confidential or proprietary information of the Company have executed and delivered a CIIA to the Company or
other form of written contract or agreement with the Company that requires such consultants to maintain the confidentiality of
such information and assigns to the Company all rights to any inventions, improvements, discoveries or information relating to
the business of the Company. The Company is not aware that any executive officer of the Company has plans to terminate his or her
employment relationship with the Company. The Company has complied in all material respects with all applicable laws relating to
wages, hours, equal opportunity, collective bargaining, workers’ compensation insurance and the payment of social security
and other taxes. None of the employees of the Company is represented by any labor union, and there is no labor strike or other
labor trouble pending or, to the Company’s knowledge, threatened with respect to the Company. To the Company’s knowledge,
no employee of the Company is obligated under any contract or subject to any judgment, decree or administrative order that would
conflict or interfere with (i) the performance of the employee’s duties as an employee, director or officer of the Company,
or (ii) the Company’s business as conducted or proposed to be conducted.

 

(s)         
Internal Control over Financial Reporting. The Company maintains a system of internal control over financial reporting
(as such is defined in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and has been
designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. The Company does not have any material weaknesses in its internal control over financial reporting.
Since the date of the latest audited financial statements included in the SEC Documents, there has been no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting.

 

(t)          
Disclosure Controls and Procedures. The Company maintains disclosure controls and procedures (as such term is defined
in Rule 13a-15(e) of the Exchange Act) that comply with the requirements of the Exchange Act. Such disclosure controls and procedures
have been designed to ensure that material information relating to the Company is accumulated and communicated to the Company’s
management, including the Company’s principal executive officer and principal financial officer, by others within those entities.

 

(u)        
Sarbanes-Oxley Compliance. The Company and the Company’s directors and officers, in their capacities as such,
are in compliance with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection
therewith (“Sarbanes-Oxley”), including Section 402 related to loans and Sections 302 and 906 related to certifications,
and neither the Company nor any of its officers has received notice from any governmental entity questioning or challenging the
accuracy, completeness, content, form or manner of filing or submission of such certifications. The Company has no reasonable basis
to believe that it will not continue to be in compliance with Sarbanes-Oxley as in effect on the Closing Date (including, without
limitation, the requirements of Section 404 thereof).

 

    	14

    	 

    

 

(v)        
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public
board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened in writing
against the Company which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or
the Securities or (ii) would reasonably be expected to result in a Material Adverse Effect.

 

(w)      
Investment Company Act. The Company is not, nor, after giving effect to the sale of the Shares and the Warrants and
the application of the proceeds therefrom, will it become, an “investment company” within the meaning of the Investment
Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

(x)        
No Market Manipulation. Neither the Company nor, to the knowledge of the Company, any of the Company’s directors,
officers, employees, agents or controlling persons have taken, directly or indirectly, any action designed, or that might reasonably
be expected, to cause or result in, under the Securities Act or otherwise, or that has constituted, stabilization or manipulation
of the price of the Common Stock.

 

(y)        
Foreign Corrupt Practices. Neither the Company nor, to the Company’s knowledge, any director, officer, agent,
employee or other person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company, (i)
directly or indirectly, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses
relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official
or employee from corporate funds; (iii) violated or is in violation of in any material respect any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other
unlawful payment to any foreign or domestic government official or employee.

 

(z)         
Brokers. Except pursuant to the agreement with BTIG, LLC (the “Placement Agent”), neither the
Company nor any of the Company's officers, directors, employees or stockholders has employed or engaged any broker or finder in
connection with the transactions contemplated by this Agreement and no other fee or other compensation is or will be due and owing
to any broker, finder, underwriter, placement agent or similar person in connection with the transactions contemplated by this
Agreement.

 

(aa)     
Regulation. Assuming the accuracy of the representations and warranties made by the Purchasers in Section 4 of this
Agreement, the offer, issuance, sale and delivery of the Securities are or will be exempt from the registration requirements of
the Securities Act and the qualification or registration provisions of applicable state securities laws. Neither the Company nor
its authorized agents have taken or will take any action that would cause the loss of such exemption. Neither the Company nor any
person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D)
in connection with the offer or sale of any of the Securities. Neither the Company nor any of its affiliates, nor any person acting
on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any
security, under circumstances that would adversely affect reliance by the Company on Section 4(2) of the Securities Act for
the exemption from registration for the contemplated transactions under this Agreement or would require registration of the Shares
or the Common Shares under the Securities Act.

 

    	15

    	 

    

 

4.                 
PURCHASERS’ REPRESENTATIONS AND WARRANTIES

 

Each Purchaser, for itself and for no other
Purchaser, hereby represents and warrants to the Company as follows:

 

(a)         
Transfer or Resale. The Purchaser understands that the Securities have not been registered under the Securities Act
or any state securities laws, and may not be offered for sale, sold, assigned or transferred without registration under the Securities
Act or an exemption therefrom and that, in the absence of an effective registration statement under the Securities Act, such Securities
may only be sold under certain circumstances as set forth in the Securities Act.

 

(b)        
Investment Purpose. The Purchaser is acquiring the Securities for its own account for investment only and not with
a view towards, or for resale in connection with, the public sale or distribution thereof. The Purchaser does not have any agreement
or understanding, directly or indirectly, with any person to distribute any of the Securities.

 

(c)         
General Solicitation. The Purchaser was contacted regarding the sale of the Securities by an authorized representative
of the Company or the Placement Agent with whom the Purchaser has a prior substantial pre-existing relationship and the Purchaser
is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities
published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any
other general solicitation or general advertisement.

 

(d)        
Information. The Purchaser (directly or through its advisors, if any) (i) has been furnished with or has had full
access to all of the publicly available information that it considers necessary or appropriate for deciding whether to purchase
the Securities, (ii) has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions
of the offering of the Securities, (iii) can bear the economic risk of a total loss of its investment in the Securities and (iv)
has such knowledge and experience in business and financial matters so as to enable it to understand the risks of and form an investment
decision with respect to its investment in the Securities. The Purchaser has received no representation or warranties from the
Company, its employees, agents (including the Placement Agent), or attorneys in making this investment decision other than as set
forth in the Transaction Documents.

 

(e)         
Reliance on Exemptions. At the time such Purchaser was offered the Securities, it was, and as of the date hereof
it is, and on each date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined
in Rule 501(a) under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under
the Securities Act. The Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of the Securities Act and that the Company is relying upon the truth and accuracy of, and the
Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser
set forth in this Agreement in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire
the Securities.

 

    	16

    	 

    

 

(f)         
No Governmental Review. The Purchaser understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability
of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)        
Authorization; Enforcement; Validity. The Purchaser is an entity duly organized and validly existing under the laws
of the jurisdiction of its organization with full right, corporate or limited partnership power and authority to enter into and
to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution,
delivery and performance by the Purchaser of the transactions contemplated by this Agreement has been duly authorized by all necessary
corporate or limited partnership action on the part of the Purchaser and any other governmental action with respect to the Purchaser.
 This Agreement has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with terms hereof,
will constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms,
except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

(h)        
No Conflicts. The execution, delivery and performance of this Agreement by the Purchaser and the consummation by
the Purchaser of the transactions contemplated hereby do not and will not (i) result in a violation of the Purchaser’s charter,
bylaws, or other similar organizational documents; (ii) conflict with, or constitute a default (or an event which with notice or
lapse of time or both would become a default) under any agreement, indenture or other instrument, obligation or understanding to
which the Purchaser is a party; or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable
to the Purchaser, except for such conflicts, defaults and violations as described in clauses (ii) or (iii) of this sentence as
would not, individually or in the aggregate, have or result in a material adverse effect on the Purchaser.

 

5.                 
RESTRICTIONS ON TRANSFER

 

(a)         
Resales. Each Purchaser agrees that the Securities may only be sold or transferred (i) pursuant to an effective registration
statement under the Securities Act (including the Registration Statement (as defined in the Registration Rights Agreement)), or
(ii) pursuant to an exemption from registration under the Securities Act.

 

    	17

    	 

    

 

(b)        
Rule 144. Each Purchaser is aware of Rule 144 promulgated by the SEC pursuant to the Securities Act (as such rule
may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially
the same purpose and effect as such rule, “Rule 144”) and the restrictions imposed thereby and further understands
and agrees that so long as such Purchaser beneficially owns 10% or more of the Company’s then outstanding securities or has
a designee selected by the Purchaser serving on the Board, the Company will deem the Purchaser to be an “affiliate”
as defined in Rule 144(a)(1) and any transfers of the Securities by the Purchaser shall be subject to the limitations applicable
to affiliates set forth in the Securities Act and the rules promulgated thereunder, including without limitation Rule 144.

 

(c)         
Legends. Each Purchaser agrees to the imprinting, so long as is required by this Section 5, of a legend on any of
the Securities in substantially the following form:

 

“THIS SECURITY HAS NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE
TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT
OR OTHER LOAN SECURED BY SUCH SECURITIES.”

 

The Company acknowledges and agrees that a Purchaser
may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest
in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a)
under the Securities Act and who agrees to be bound by the provisions of this Agreement and the Registration Rights Agreement and,
if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge.
At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or
secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the
Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required
prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately
amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.

 

    	18

    	 

    

 

 

 

(d)        
Legend Removal. The Company shall cause its counsel to promptly issue a legal opinion to the transfer agent for the
Common Stock with respect to removal of the legend set forth in Section 5(c) above, (i) following any sale of such Shares or Warrant
Shares pursuant to an effective registration statement, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule
144, or (iii) when such Shares or Warrant Shares may be sold under Rule 144, without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such Shares and Warrant Shares and without volume or manner-of-sale
restrictions.

 

6.                 
BOARD COMPOSITION

 

(a)         
Board Composition Following the Initial Closing; Appointment of Director Designees. The Board shall take all actions
necessary such that immediately following the Initial Closing, the Board shall consist of seven (7) members and shall be composed
as follows:

 

(i)   the Class I directors with a term ending at
the 2013 annual meeting of stockholders shall consist of one independent director (who shall initially be William C. Mills III)
and one director designated by the Series A-1 Stockholder (who shall initially be James Weaver) (a “Series A-1 Designee”);

 

(ii)   the Class II directors with a term ending
at the 2014 annual meeting of stockholders shall consist of the Company’s Chief Executive Officer and one director designated
by Bay City Capital Fund V, L.P. (who shall initially be Dayton Misfeldt) (a “Purchaser Designee”); and

 

(iii)   the Class III directors with a term ending
at the 2015 annual meeting of stockholders shall consist of one director designated by the Series A-1 Stockholder (who shall initially
be Roger C. Colman) (a “Series A-1 Designee”), one director designated by the Series B Stockholder (who shall
initially be Goran Jurkovic) (the “Series B Designee”) and one director designated by the by Bay City Capital
Fund V, L.P. (who shall initially be Lionel Carnot) (a “Purchaser Designee”).

 

The Series A-1 Designees, the Series B Designee and the Purchaser
Designees, shall be collectively referred to herein as the “Director Designees.” Each of the shareholders entitled
to designate a director hereunder is referred to herein as a “Designor.” The rights provided under this Section
6 are the exclusive rights of each such Designor and are not transferable.

 

(b)        
Nominations of Director Designees. For so long as a Designor’s ownership of the outstanding Common Stock of
the Company is at least five percent (5%), any Director Designee (including any successor pursuant to Subsection 6(d) below) designated
by such Designor shall be nominated by the Board of Directors (or a committee thereof) for election at the annual meeting of stockholders
at which such Director Designee’s term will expire. At least ninety (90) days prior to any such annual meeting at or by which
directors are to be elected, such Designor shall notify the Company in writing of the Director Designee to be nominated for election
as a director. The Company shall disclose in its proxy the nominated Director Designee(s). In the absence of any such notification,
it shall be presumed that the Designor’s then incumbent Director Designee(s) has been designated.

 

    	19

    	 

    

 

(c)         
Successor Director Designees. If a Director Designee shall cease to serve as a director for any reason, the Designor
of such Director Designee shall notify the Company in writing of the individual to replace such Director Designee, and the Company’s
Board of Directors shall appoint and elect such replacement director to serve out the remaining term of the existing director.

 

(d)        
Indemnification Agreements. The Company shall enter into an Indemnification Agreement with each Purchaser Designee
prior to the commencement of his or her service on the Board, in substantially the form attached as Exhibit B.

 

(e)         
Committees of the Board of Directors. For so long as the Designor of the Purchaser Designees has the right to designate
Director Designees and provided that such individuals meet the requirements imposed by the SEC or any exchange upon which the Common
Stock may be traded for membership on such committees, the Board shall appoint a Purchaser Designee to the Audit Committee, the
Compensation Committee and the Nominating and Governance Committee. For so long as the Designor of the Series A Designees has the
right to designate Director Designees and provided that such individual meets the requirements imposed by the SEC or any exchange
upon which the Common Stock may be traded for membership on such committee, the Board shall appoint a Series A Designee to the
Audit Committee.

 

(f)         
Amendment of this Section 6. For so long as the Series A-1 Stockholder has the right to designate a Series A-1 Designee,
no provision of this Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case
of an amendment, by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment
shall be binding on all Purchasers) and the Series A-1 Stockholder or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought. For so long as the Series B Stockholder has the right to designate the Series B Designee,
no provision of this Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case
of an amendment, by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment
shall be binding on all Purchasers) and the Series B Stockholder or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought.

 

(g)        
Board Observer Rights. For so long as a Growth Equity Opportunities Fund III, LLC’s (“GEOF”)
ownership of the outstanding Common Stock of the Company is at least five percent (5%), GEOF shall have the right to have a representative
(the “Observer”) attend each meeting of the Board. The Company shall deliver to the Observer notice of such
meetings in accordance with the Company’s Bylaws. Copies of any materials distributed to members of the Board shall likewise
be provided to the Observer in a timely fashion. The Company shall not be required to deliver to the Observer specific information,
and may preclude the Observer

 

    	20

    	 

    

 

from specific discussions of
the Board of Directors concerning specific information, that (i) is determined by the Board of Directors of the Company to be competitively
sensitive, (ii) the Board of Directors of the Company determines is attorney-client privileged and should not, therefore, be disclosed
or (iii) the Board of Directors of the Company determines is reasonably necessary to preserve or protect the exercise of the Board
of Directors’ fiduciary duty or to avoid a possible conflict of interest. GEOF agrees, and any representative of GEOF, including
the Observer, will agree, to hold in confidence and trust and not disclose (other than to GEOF or its affiliates) or use any confidential
information provided to or learned by it in connection with its rights under this letter, provided, that GEOF may give access to
such confidential information to its officers, directors, employees, accountants, counsel and other representatives (collectively,
“Representatives”) if each such Representative is informed of the confidential nature of the information and
that the information is subject to a confidentiality agreement and each such Representative is otherwise under an obligation to
keep such confidential information confidential. Each Observer shall execute a non-disclosure agreement with the Company in form
and substance reasonably satisfactory to the Company prior to commencing his or her role as an Observer. The rights set forth in
this Section 6(g) may not be assigned by GEOF without the prior written consent of the Company.

 

7.                 
OTHER AGREEMENTS AND COVENANTS

 

(a)         
Shareholder Meeting. Within 30 calendar days of the Initial Closing Date, the Company shall cause to be prepared
and filed with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for its 2013
Annual Meeting of Shareholders (the “2013 Annual Meeting”), which proxy statement shall include proposals to
obtain approval by the Company’s shareholders of (a) an increase in the number of authorized shares of Common Stock under
the Company’s Charter from 150,000,000 shares to 300,000,000 shares (the “Shareholder Approval of Increase in Authorized
Shares”) and (b) the 2013 Plan (as defined below in Section 7(c)). Upon approval by the SEC of such preliminary
proxy or, if the SEC has not reviewed such, at the expiration of 10 calendar days from the filing of the preliminary proxy statement,
the Company shall file a definitive proxy statement or consent solicitation statement and call and hold the 2013 Annual Meeting
within 50 calendar days of the filing of such definitive proxy statement.

 

(b)        
National Market Listing. Following the Initial Closing, the Company will work with the Purchasers and advisors to
qualify for and obtain a full national market listing of its Common Stock on either the NASDAQ Capital Market or the NYSE MKT.
The Company will use commercially reasonable efforts to qualify and apply for such listing, including effecting a reverse split
of its common stock, subject to shareholder approval, if deemed advisable by a majority of the Board.

 

(c)         
Option Pool. Following the Initial Closing, the Board will, subject to shareholder approval at the 2013 Annual Meeting,
approve the 2013 Employee, Consultant and Director Stock Plan (the “2013 Plan”), such that the total number
of shares of Common Stock subject to outstanding options together with the shares of Common Stock available for issuance under
the 2013 Plan and the Company’s 2012 Employee Stock Purchase Plan shall be equal 7.0% of the Company’s fully diluted
shares outstanding immediately following the Initial Closing.

 

    	21

    	 

    

 

(d)        
Use of Proceeds. Except with respect to the use of proceeds to repay all accrued and unpaid interest on the Debt
immediately following the Closing, the proceeds from the sale of the Shares and Warrants under this Agreement shall be used for
working capital and general corporate purposes.

 

(e)         
Certificate of Elimination. As promptly as practicable following the Initial Closing, the Company shall file a Certificate
of Elimination of the Series A-1 Preferred Stock and Series B Preferred Stock (the “Certificate of Elimination”)
under Section 151(g) of the General Corporation Law of the State of Delaware with the Secretary of State of the State of Delaware.

 

(f)         
Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under
Regulation D and, promptly upon request of any Purchaser, to provide a copy thereof. The Company shall take such action as the
Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to
the Purchasers at each Closing under applicable securities or “Blue Sky” laws of the states of the United States, and
shall provide evidence of such actions promptly upon request of any Purchaser. The Company shall make all filings and reports relating
to the offer and sale of the Securities to the Purchasers required under applicable securities or “Blue Sky” laws of
the states of the United States following each Closing Date.

 

(g)        
Reservation of Shares. As of the date hereof, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants, in each case
issued as of the Initial Closing (subject to receipt of Shareholder Approval of Increase in Authorized Shares with respect to certain
Warrant Shares).  Subject to receipt of Shareholder Approval of Increase in Authorized Shares, the Company shall have reserved,
and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares
of Common Stock for the purpose of enabling the Company to issue all such additional Shares and additional Warrant Shares pursuant
to any exercise of the Warrants, in each case issued in any Subsequent Closing.

 

(h)        
Exchange Act Filings. Until such time that all of the Securities may be sold without the requirement for the Company
to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, the Company covenants
to use commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace
period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.

 

(i)          
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect
of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities
in a manner that would require the registration under the Securities Act of the sale of the Securities or that would be integrated
with the offer or sale of the Securities for purposes of the rules and regulations of any trading market such that it would require
shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing
of such subsequent transaction.

 

    	22

    	 

    

 

(j)          
Expenses. The Company shall pay the reasonable legal and other fees and expenses of the Purchasers incurred in connection
with the transactions contemplated by this Agreement, up to a maximum of $50,000 in the aggregate, whether or not the Initial Closing
occurs. In the event the Initial Closing occurs, the Company shall pay the reasonable legal fees and expenses of the Purchasers
incurred in connection with the transactions contemplated by this Agreement, up to a maximum of $100,000 in the aggregate. Each
party shall otherwise bear all costs and expenses incurred by such party in connection with the transactions contemplated by this
Agreement.

 

(k)        
Purchaser/Director Designee Exchange Act Filings.  Each Purchaser and each Director Designee shall be responsible
for the filing (and for all expenses in connection therewith) of required filings under the Exchange Act and all required amendments
thereto relating to ownership of the Securities and appointment as a member of the Board, including any required Forms 3, 4 and
5 and Schedules 13D or 13G (as applicable). Each Purchaser and each Director Designee shall use commercially reasonable efforts
to file such forms within the time period allowed for such forms under the rules and regulations promulgated by the SEC.

 

8.                 
PUBLIC STATEMENTS

 

The Company shall, by 9:00 a.m. (New York
City time) on the trading day immediately following the date of this Agreement, issue a press release disclosing the material terms
of the transactions contemplated hereby. The Company shall file a Current Report on Form 8-K within the time required by Form 8-K
disclosing the material terms of the transactions contemplated hereby, which Form 8-K shall include this Agreement (including conformed
signature pages thereto), the Registration Rights Agreement (including conformed signature pages thereto) and the form of Warrant
as exhibits thereto. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect
to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or
without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law.

 

9.                 
MISCELLANEOUS

 

(a)         
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by the internal laws of the State of Delaware, United States of America, without giving effect to any choice
of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the
application of the laws of any jurisdictions other than the State of Delaware. If any provision of this Agreement shall be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction.

 

    	23

    	 

    

 

(b)        
Entire Agreement. This Agreement and the documents referenced herein and therein constitute the entire agreement
among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties
or undertakings, other than those set forth or referred to herein and therein. This Agreement and the documents referenced herein
and therein supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof
and thereof. Notwithstanding the foregoing, the terms of any confidentiality agreement entered into between the Company and any
Purchaser shall remain in full force and effect.

 

(c)         
Amendments and Waivers. Except as otherwise set forth herein, no provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding
at least a majority in interest of the Shares then outstanding (which amendment shall be binding on all Purchasers) or, in the
case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(d)        
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii)
upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept
on file by the sending party); (iii) upon receipt when delivered by email delivery of a “.pdf” format data file or
(iv) upon receipt, when sent via a nationally recognized overnight delivery service, in each case properly addressed to the party
to receive the same. The addresses, facsimile numbers and email addresses for such communications shall be:

 

	If to the Company: 	Interleukin Genetics,
Inc.
	 	135 Beaver Street
 Waltham, MA 02452
 Telephone:  (781) 398-0700
 Facsimile:     (781) 398-0720
 email:            kkornman@ilgenetics.com
 Attention:    Kenneth S. Kornman
                       Chief Executive Officer
	 	 
	with a copy to: 	Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C.

	 	
        One Financial Center

        Boston, MA 02111

        Tel: (617) 542-6000

        Fax: (617) 542-2241

        email:bkeane@mintz.com

        Attn: Brian P. Keane, Esq.

         

	If to a Purchaser: 	To the address
set forth on the signature page to this Agreement.

    	24

    	 

    

  

(e)         
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.

 

(f)         
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and
things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

(g)        
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

(h)        
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of each Purchaser (other than by merger, consolidation or sale of all or substantially all of the Company’s assets).
Except as specifically set forth herein, any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of this Agreement and the documents referenced herein that apply to the Purchasers.

 

(i)          
Survival. Subject to applicable statute of limitations, the representations and warranties contained herein shall
survive the Closing and the delivery of the Securities hereunder. No investigation by or knowledge of a party or its representatives,
before or after the date of this Agreement, will affect in any manner the representations, warranties, covenants or agreements
of another party set forth in this Agreement (or in any document to be delivered in connection with the consummation of the transactions
contemplated by this Agreement) or the rights to rely thereon, and such representations, warranties, covenants and agreements will
survive any such investigation.

 

(j)          
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person or
entity.

 

(k)        
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in
the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs (including customary indemnity or bond) associated with the
issuance of such replacement Securities.

 

    	25

    	 

    

  

(l)          
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein or in any
other document referred to herein, and no action taken by any Purchaser pursuant hereof or thereto, shall be deemed to constitute
the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the
Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by
this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation,
the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party
in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of this Agreement and the other documents referred to herein.

 

(m)      
Business Day. “Business Day” means any day except any Saturday, any Sunday, any day which is a
federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or
required by law or other governmental action to close. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein or in the Registration Rights Agreement shall not be a Business Day, then such action may
be taken or such right may be exercised on the next succeeding Business Day.

 

(n)        
Headings. The headings of this Agreement are for convenience of reference only and shall not limit or otherwise affect
the meaning hereof.

 

(o)        
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.

 

[Remainder of page intentionally left blank.
Signature pages follow.]

 

    	26

    	 

    

IN WITNESS WHEREOF, the parties hereto have
caused this Common Stock Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.

 

	COMPANY:
	 
	INTERLEUKIN GENETICS, Inc.
	By: /s/ Kenneth S. Kornman

Name: Kenneth S. Kornman

Title: Chief Executive Officer

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGES FOR PURCHASERS FOLLOW]

    	 

    	 

    

 

[PURCHASER SIGNATURE PAGES TO INTERLEUKIN
GENETICS, INC. 

COMMON
STOCK PURCHASE AGREEMENT]

 

IN WITNESS WHEREOF,
the undersigned have caused this Common Stock Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

Name of Purchaser: See Schedule I.

 

Signature of Authorized Signatory of
Purchaser: __________________________________

 

Name of Authorized Signatory: ____________________________________________________

 

Title of Authorized Signatory: _____________________________________________________

 

Email Address for Notice to Purchaser:
______________________________________________

 

Facsimile Number for Notice to Purchaser: _____________________________________________

 

Address for Notice to Purchaser:

 

 

  

Address for Delivery of Securities to Purchaser (if not same
as address for notice):

 

 

 

 

Purchase Price: $_________________

 

Shares of Common Stock: _________________

 

Warrant Shares: __________________

 

EIN Number: __________________

 

 

 

[SIGNATURE PAGES CONTINUE]

 

    	 

    	 

    

SCHEDULE I

 

The Purchasers

	 	Initial Closing	Subsequent Closings
	
         

        Purchaser
	
         

        Shares
	Warrant Shares	Purchase Price	
         

        Shares
	Warrant Shares	
         

        Purchase Price

	
        Bay City Capital Fund V, L.P.

         
	20,187,464	15,140,598	$5,541,458.87	8,411,443	6,308,582	$2,308,941.10
	
        Bay City Capital Fund V Co-Investment Fund

         
	384,699	288,524	$105,599.88	160,291	120,218	$43,999.88
	
        Growth Equity Opportunities Fund III, LLC

         
	15,429,122	11,571,842	$4,235,293.99	6,428,801	4,821,601	$1,764,705.87
	
        Merlin Nexus IV, LP

         
	5,143,041	3,857,281	$1,411,764.75	2,142,935	1,607,201	$588,235.66
	
        Condor Trading LP

         
	364,298	273,223	$99,999.80	151,791	113,843	$41,666.63
	
        Millennium Trust Company, LLC, Custodian FBO Keith C. Stone
        IRA

         
	246,009	184,507	$67,529.47	102,504	76,878	$28,137.35
	
        Millennium Trust Company, LLC, Custodian FBO Keith C. Stone
        Roth IRA

         
	118,290	88,717	$32,470.60	49,287	36,965	$13,529.28
	
        CDB Advisory Group, LLC

         
	1,457,195	1,092,896	$400,000.03	607,164	455,373	$166,666.52
	
        Millennium Trust Company, LLC, Custodian FBO Michael Bird IRA

         
	301,940	226,455	$82,882.53	125,808	94,356	$34,534.30
	Millennium Trust Company, LLC, Custodian FBO Michael Bird Roth IRA	83,789	62,842	$23,000.08	34,912	26,184	$9,583.34
	Total	43,715,847	32,786,885	$12,000,000	18,214,936	13,661,201	$4,999,999.93Exhibit 10.2

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (this “Agreement”) is made and entered into as of May 17, 2013, between Interleukin Genetics, Inc.,
a Delaware corporation (the “Company”), each of the several purchasers signatory hereto (each such purchaser,
a “Purchaser” and, collectively, the “Purchasers”), Pyxis Innovations Inc., a Delaware corporation
(“Pyxis”), Delta Dental Plan of Michigan Inc., a Michigan nonprofit corporation (“DDMI”),
and BTIG, LLC, a broker-dealer registered with the Financial Industry Regulatory Authority, Inc. (the “Placement Agent”).

 

This Agreement is made
pursuant to the Common Stock Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase
Agreement”).

 

The Company, each Purchaser,
Pyxis, DDMI and the Placement Agent hereby agree as follows:

 

		1.	Definitions.

 

Capitalized terms
used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the
Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

“Advice”
shall have the meaning set forth in Section 6(d).

 

“Conversion
Shares” means the shares of Common Stock issuable upon the Preferred Stock Conversion and the Debt Conversion.

 

“Effectiveness
Date” means, with respect to any Registration Statement required to be filed hereunder, the fifth Trading Day following
the date on which the Company is notified by the SEC that such Registration Statement will not be reviewed or is no longer subject
to further review and comments.

 

“Effectiveness
Period” shall have the meaning set forth in Section 2(a).

 

“Event”
shall have the meaning set forth in Section 2(b).

 

“Event
Date” shall have the meaning set forth in Section 2(b).

 

“Filing
Date” means, (i) with respect to the Initial Registration Statement required hereunder, the 45th calendar
day following the Initial Closing Date, (ii) with respect to any additional Registration Statements which may be required pursuant
to Section 3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration
Statement related to the Registrable Securities, and (iii) with respect to the Subsequent Closing Registration Statement, the 45th
calendar day following the Expiration Date.

    	 

    	 

    

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Plan
of Distribution” shall have the meaning set forth in Section 2(a).

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
by the SEC pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms
of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and
supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be
incorporated by reference in such Prospectus.

 

“Registrable
Securities” means, as of any date of determination, (i) with respect to the Initial Registration Statement (a) all Shares
sold in the Initial Closing, (b) all Warrant Shares then issuable upon exercise of the Warrants issued in the Initial Closing,
(c) the Conversion Shares, (d) all shares of Common Stock then issuable upon exercise of the warrants issued to the Placement Agent
in connection with the Initial Closing and (e) any securities issued or then issuable upon any stock split, dividend or other distribution,
recapitalization or similar event with respect to the foregoing, and (ii) with respect to the Subsequent Closing Registration Statement
(a) all Shares sold in any Subsequent Closing, (b) all Warrant Shares then issuable upon exercise of the Warrants issued in any
Subsequent Closing, (c) all shares of Common Stock then issuable upon exercise of the warrants issued to the Placement Agent in
connection with any Subsequent Closing and (d) any securities issued or then issuable upon any stock split, dividend or other distribution,
recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities
shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another,
Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of
such Registrable Securities is declared effective by the SEC under the Securities Act and such Registrable Securities have been
disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously
sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions
and without current public information pursuant to Rule 144 (assuming that all Warrants are exercised by “cashless exercise”
as provided in Section 2(c) of each of the Warrants), as reasonably determined by the Company, upon the advice of counsel to the
Company.

 

    	2

    	 

    

 

“Registration
Deadline” means, with respect to any Registration Statement required hereunder, the 90th calendar day following
the Filing Date.

 

“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional
registration statements contemplated by Section 3(c), including (in each case) the Prospectus, amendments and supplements to any
such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material
incorporated by reference or deemed to be incorporated by reference in any such registration statement.

 

“Rule
415” means Rule 415 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect
as such Rule.

 

“Rule
424” means Rule 424 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect
as such Rule.

 

“Selling
Stockholder Questionnaire” shall have the meaning set forth in Section 3(a).

 

“SEC
Guidance” means (i) any publicly-available written or oral guidance of the SEC staff, or any comments, requirements or
requests of the SEC staff and (ii) the Securities Act.

 

“Subsequent
Closing Registration Statement” means the Registration Statement filed pursuant to this Agreement to register the resale
of (a) all Shares sold in any Subsequent Closing, (b) all Warrant Shares then issuable upon exercise of the Warrants issued in
any Subsequent Closing, (c) all shares of Common Stock then issuable upon exercise of the warrants issued to the Placement Agent
in connection with any Subsequent Closing and (d) any securities issued or then issuable upon any stock split, dividend or other
distribution, recapitalization or similar event with respect to the foregoing.

 

    	3

    	 

    

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the New
York Stock Exchange, the OTCQB or the OTC Bulletin Board (or any successors to any of the foregoing).

 

		2.	Shelf Registration.

 

		(a)	On or prior to each Filing Date, the Company shall prepare and file with the SEC a Registration
Statement covering the resale of all or such maximum portion of the Registrable Securities as permitted by SEC Guidance (provided
that, the Company shall use its reasonable best efforts to obtain the registration of all of the Registrable Securities in accordance
with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09) that are not then registered
on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration
Statement filed hereunder shall be on the appropriate form under the Securities Act and shall contain (unless otherwise directed
by at least a majority in interest of the Holders) substantially the “Plan of Distribution” attached hereto
as Annex A. Subject to the terms of this Agreement, the Company shall use its reasonable best efforts to cause a Registration
Statement filed hereunder to be declared effective under the Securities Act as promptly as reasonably practicable after the filing
thereof, but in any event prior to the applicable Effectiveness Date, and shall use its reasonable best efforts to keep such Registration
Statement current and continuously effective under the Securities Act until such date as all Registrable Securities covered by
such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) in the opinion of counsel to the Holders,
(A) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and (B) (I) may be sold without the requirement
for the Company to be in compliance with the current public information requirement under Rule 144 or (II) the Company is in compliance
with the current public information requirement under Rule 144 (the “Effectiveness Period”). Such Registration
Statement (including any amendments or supplements thereto and prospectuses contained therein), except for information provided
by a Holder or any transferee of a Holder, shall not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading. The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. New
York City time on a Trading Day. The Company shall immediately

    	4

    	 

    

 

notify the Holders via facsimile
or by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms
effectiveness with the SEC, which shall be the date requested for effectiveness of such Registration Statement. The Company shall,
by 9:30 a.m. New York City time on the Trading Day after the effective date of such Registration Statement, file a final Prospectus
with the SEC as required by Rule 424. Notwithstanding any other provision
of this Agreement, if any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered
on a particular Registration Statement (and notwithstanding that the Company used its reasonable best efforts to obtain the registration
of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable
Securities, the number of Registrable Securities to be registered on such Registration Statement will first be reduced by Registrable
Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be registered, to the Holders on a
pro rata basis based on the total number of unregistered Warrant Shares held by such Holders). In the event of a cutback hereunder,
the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to such Holder’s
allotment. 

 

(b)              
If: (i) a Registration Statement is not filed on or prior to its Filing Date, (ii) the Company fails to use its reasonable
best efforts to obtain effectiveness with the SEC prior to the Registration Deadline of a Registration Statement, (iii) the Company
fails to file with the SEC a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the
SEC pursuant to the Securities Act, within five Trading Days of the date that the Company is notified (orally or in writing, whichever
is earlier) by the SEC that such Registration Statement will not be “reviewed” or will not be subject to further review,
or (iv) prior to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise
respond in writing to comments made by the SEC in respect of such Registration Statement within twenty (20) calendar days after
the receipt of comments by or notice from the SEC that such amendment is required in order for such Registration Statement to be
declared effective, (any such failure or breach being referred to as an “Event”, and for purposes of clauses
(i) and (ii) the date on which such Event occurs, and for purpose of clause (iii) the date on which such five (5) Trading Day period
is exceeded, and for purpose of clause (iv) the date which such twenty (20) calendar day period is exceeded, being referred to
as “Event Date”), then, in addition to any other rights the Holders may have hereunder or under applicable law,
on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured
by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated
damages and not as a penalty, equal to 2% of the aggregate purchase price paid by such Holder pursuant to (i) the Purchase Agreement
in the case of the Purchasers, (ii) that certain Stock Purchase Agreement by and between the Company and Pyxis dated as of March
5, 2003, as amended, in the case of Pyxis, or (iii) that certain Stock Purchase Agreement by and between the

 

    	5

    	 

    

 

Company and DDMI dated June 29,
2012 in the case of DDMI, for any unregistered Registrable Securities then held by such Holder; provided, however,
that the Company shall not be required to pay partial liquidated damages to such Holder under this Section 2(b) in an aggregate
amount (excluding any interest paid thereon) in excess of 5% of the aggregate Subscription Amount paid by such Holder pursuant
to aforementioned agreements. The parties agree that the Company shall not be liable for liquidated damages under this Agreement
with respect to any unexercised Warrants or Warrant Shares. If the Company fails to pay any partial liquidated damages pursuant
to this Section in full within seven (7) days after the date payable, the Company will pay interest thereon at a rate of 18% per
annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date
such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated
damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.

 

		3.	Registration Procedures.

 

In connection with
the Company’s registration obligations hereunder, the Company shall:

 

(a)               
Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading
Day prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be
incorporated or deemed to be incorporated therein by reference, but not including (i) any Exchange Act filing (including any post-effective
amendment filed solely to update the Registration Statement for an Exchange Act filing) or (ii) any supplement or post-effective
amendment to a registration statement that is not related to such Holder’s Registrable Securities), the Company shall (i)
furnish to each Holder copies of all such documents proposed to be filed and any comments made by the staff of the SEC with respect
to such Registration Statement and the Company’s responses thereto, which documents (other than those incorporated or deemed
to be incorporated by reference) will be subject to the review of such Holders, and (ii) cause its officers and directors, counsel
and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of
respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company
shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of
a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is notified of such
objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration Statement
or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto.
In the event that the Company is prevented from making such filing on account of the objections described in the previous sentence
(provided that the Company uses reasonable best efforts to address the objections described in the previous sentence and to promptly
file thereafter), the failure of the Company to make such filing shall not be deemed a breach or default hereunder or otherwise
with respect to the Securities. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to
this Agreement as Annex B (a “Selling Stockholder Questionnaire”) on a date that is not less than two
(2) Trading Days prior to the Filing Date or by the end of the fourth (4th) Trading Day following the date on which
such Holder receives draft materials in accordance with this Section.

 

    	6

    	 

    

  

(b)              
(i) Prepare and file with the SEC such amendments, including post-effective amendments, and supplements to a Registration
Statement and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement current and continuously
effective (subject to any requirement that a post-effective amendment be declared effective by the SEC) as to the applicable Registrable
Securities for the Effectiveness Period and prepare and file with the SEC such additional Registration Statements in order to register
for resale under the Securities Act all of the Registrable Securities subject to any SEC Guidance that sets forth a limitation
on the number of Registrable Securities permitted to be registered on a particular Registration Statement, (ii) cause the related
Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as
so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments
received from the SEC with respect to a Registration Statement or any amendment thereto, and (iv) comply in all material respects
with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities
covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the
intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus
as so supplemented.

 

(c)               
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares
of Common Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but
in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not
less than the number of such Registrable Securities. The Company shall use its best efforts to cause such new Registration Statement
to become effective as soon as practicable following the filing thereof. For all purposes of this Agreement, such additional Registration
Statement shall be deemed to be the Registration Statement required to be filed by the Company pursuant to Section 2(a), and the
Company and the Investors shall have the same rights and obligations with respect to such additional Registration Statement as
they shall have with respect to the initial Registration Statement required to be filed by the Company pursuant to Section 2(a).

 

    	7

    	 

    
 

(d)              
Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof,
be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as
reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested
by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A), when a Prospectus
or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed (but not including
(1) any Exchange Act filing (including any post-effective amendment filed solely to update the Registration Statement for an Exchange
Act filing) or (2) any supplement or post-effective amendment to a registration statement that is not related to such Holder’s
Registrable Securities), (B) when the SEC notifies the Company whether there will be a “review” of such Registration
Statement and whenever the SEC comments in writing on such Registration Statement, and (C) with respect to a Registration Statement
or any post-effective amendment, when the same has become effective, (ii) of any request by the SEC or any other federal or state
governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii)
of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness
of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose,
(iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification
of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such
purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement
ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or
deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration
Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be,
it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading and (vi) of
the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material
and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability
of a Registration Statement or Prospectus, provided that, any and all of such information shall remain confidential to each Holder
until such information otherwise becomes public, unless disclosure by a Holder is required by law.

 

(e)               
Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping
or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification)
of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

    	8

    	 

    

  

(f)               
Furnish to each Holder, upon request, without charge, at least one conformed copy of each such Registration Statement and
each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein
by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously
furnished or incorporated by reference) promptly after the filing of such documents with the SEC; provided, that any such item
which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.

 

(g)              
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or
supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered
by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).

 

(h)              
 The Company shall cooperate with any broker-dealer through which a Holder proposes to resell its Registrable Securities
in effecting a filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110, as requested by any such Holder.

 

(i)                
Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify
or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the Registration
or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions
within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption
therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable
the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement; provided, that, the
Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject
the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of
process in any such jurisdiction.

 

(j)                
If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free,
to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be
in such denominations and registered in such names as any such Holder may request.

 

    	9

    	 

    

  

(k)              
Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances
taking into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of
the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration
Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference,
and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading. If
the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any
Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus.
The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.
The Company shall be entitled to exercise its right under this Section 3(k) to suspend the availability of a Registration Statement
and Prospectus for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.

 

(l)                
Comply with all applicable rules and regulations of the SEC in connection with obtaining and maintaining the effectiveness
of any Registration Statement required to be filed and maintained with the SEC hereunder.

 

(m)            
To the extent reasonably required, request that each selling Holder shall furnish to the Company a certified statement as
to the number of shares of Common Stock beneficially owned by such Holder, if required by the SEC, the natural persons thereof
that have voting and dispositive control over such shares. During any periods that the Company is unable to meet its obligations
hereunder with respect to the registration of the Registrable Securities solely because any Holder fails to furnish such information
within five (5) Trading Days of the Company’s request, any liquidated damages that are accruing at such time as to such Holder
only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only,
until such information is delivered to the Company.

 

(n)              
At the reasonable request of a Holder and at such Holder’s expense, prepare and file with the SEC such amendments
(including post-effective amendments) and supplements to a Registration Statement and any Prospectus used in connection with the
registration statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement.

 

    	10

    	 

    

  

(o)              
Hold in confidence and not make any disclosure of information concerning a Holder provided to the Company (excluding any
information provided on the Selling Stockholder Questionnaire) unless (i) disclosure of such information is necessary to comply
with federal or state securities laws or the rules of any securities exchange or trading market on which the Company’s securities
are then listed or traded, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission
in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other order from a court
or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other
than by disclosure in violation of this or any other agreement. The Company agrees that it shall, upon learning that disclosure
of such information concerning a Holder is sought in or by a court or governmental body of competent jurisdiction or through other
means, give prompt notice to such Holder prior to making such disclosure, and allow such Holder, at its expense, to undertake appropriate
action to prevent disclosure of, or to obtain a protective order for, such information

 

4.             Registration Expenses. All
fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company
whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the
foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees
and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with
the SEC, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading
and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including,
without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions
of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable
Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities
Act liability insurance, if the Company so desires such insurance, (vi) fees and disbursements of one counsel for the Holders selected
by Holders of at least a majority of the Registrable Securities included in the applicable Registration Statement, not to exceed
$10,000 for each such Registration Statement, and (vii) fees and expenses of all other Persons retained by the Company in connection
with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all
of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including,
without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense
of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities
exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder
or, except as set forth under (vi) above and to the extent provided for in the Purchase Agreement, any legal fees or other costs
of the Holders.

 

    	11

    	 

    

 

		5.	Indemnification.

 

(a)               
Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify,
hold harmless and defend each Holder, the officers, directors, members, managers, partners, agents, brokers (including brokers
who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of
shares of Common Stock), investment advisors and employees (and any other persons with a functionally equivalent role of a person
holding such titles, notwithstanding a lack of such title or any other title) of each of them, each person who controls any such
Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors,
members, stockholders, partners, agents and employees (and any other persons with a functionally equivalent role of a person holding
such titles, notwithstanding a lack of such title or any other title) of each such controlling person, to the fullest extent permitted
by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable
attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to (1)
any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of
prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of
any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act or any other law, including any state securities law,
or any rule or regulation promulgated thereunder, in connection with the performance of its obligations under this Agreement, except
to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding
such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information
relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement
thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (ii) in the case of an occurrence
of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable
Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable
for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(d). The Company shall notify
the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions
contemplated by this Agreement of which the Company is aware.

 

    	12

    	 

    

  

(b)              
Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company,
its directors, officers, agents and employees, each person who controls the Company (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling persons, to the fullest
extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon
(x) such Holder’s failure to comply with the prospectus delivery requirements of the Securities Act or (y) any untrue or
alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact
required to be stated therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they
were made) or necessary to make the statements therein not misleading (i) to the extent, but only to the extent, that such untrue
statement or omission is contained in any information so furnished in writing by such Holder to the Company in such Holder’s
capacity as a selling Holder specifically and expressly for inclusion in such Registration Statement or such Prospectus or (ii)
to the extent that such information relates to such Holder’s proposed method of distribution of Registrable Securities and
was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement (it being understood
that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any amendment or supplement thereto or (ii)
in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated,
defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated,
defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in
Section 6(d). In no event shall the liability of any selling Holder under this Section 5(b) be greater in amount than the dollar
amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification
obligation.

 

(c)               
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any person entitled
to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the person from
whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right
to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment
of all fees and expenses reasonably incurred in connection with defense thereof; provided that the failure of any Indemnified Party
to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except
(and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) that such failure shall have materially prejudiced the Indemnifying Party’s ability to defend
such action.

 

    	13

    	 

    

 

 

An Indemnified
Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense
of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named
parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party,
and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same
counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies
the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying
Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate
counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any
such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying
Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect
of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from
all liability on claims that are the subject matter of such Proceeding.

 

Subject to
the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses
to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with
this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying
Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and
expenses applicable to such actions for which such Indemnified Party is judicially determined not to be entitled to indemnification
hereunder.

 

(d)              
Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient
to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable
by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified
Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among
other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or
alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such
party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification
provided for in this Section was available to such party in accordance with its terms.

 

    	14

    	 

    

  

The parties
hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the
immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to contribute
pursuant to this Section 5(d), in the aggregate, any amount in excess of the amount by which the net proceeds actually received
by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such
Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.

 

The indemnity
and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to
the Indemnified Parties, provided that no amount shall be reimbursed twice in any event.

 

		6.	Miscellaneous.

 

(a)               
Remedies. In the event of a breach by the Company or by a Holder of any of their respective obligations under this
Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law
and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement.
Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred
by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action
for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be
adequate.

 

(b)              
No Piggyback on Registrations. Neither the Company nor any of its security holders (other than the Holders in such
capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities.

 

(c)               
Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the
Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to a Registration Statement.

 

(d)              
Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of
a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will
forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing
(the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or
amended) may be resumed. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed
as promptly as is practicable.

 

    	15

    	 

    

  

(e)               
Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall
be in writing and signed by the Company and (i) the Holders of a majority of the then outstanding Registrable Securities (including,
for this purpose any Registrable Securities issuable upon exercise or conversion of any Security) originally issued to the Purchasers,
(ii) Pyxis and (iii) DDMI. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver
or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each
Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities
shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions
hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or
indirectly affect the rights of other Holders may be given by such Holder or Holders of all of the Registrable Securities to which
such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended, modified,
or supplemented except in accordance with the provisions of the first sentence of this Section 6(e).

 

(f)               
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be delivered as set forth in the Purchase Agreement.

 

(g)              
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its
rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities.
Each Holder may assign their respective rights hereunder in the manner and as permitted under Section 9(h) of the Purchase Agreement.

 

(h)              
No Inconsistent Agreements; Prior Agreements Terminated. Neither the Company nor any of its subsidiaries has entered,
as of the date hereof, nor shall the Company or any of its subsidiaries, on or after the date of this Agreement, enter into any
agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement
or otherwise conflicts with the provisions hereof. Neither the Company nor any of its subsidiaries has previously entered into
any agreement granting any registration rights with respect to any of its securities to any person or entity that have not been
satisfied in full or waived with respect to any Registration Statement filed under this Agreement. This agreement shall supersede
and replace the following agreements, which are terminated as of the date hereof: (i) the Registration Rights Agreement, dated
March 5, 2003, by and between the Company and Pyxis and (ii) the Registration Rights Agreement, dated June 29, 2012, by and between
the Company and DDMI.

 

    	16

    	 

    

 

(i)                
Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.

 

(j)                
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be determined in accordance with the provisions of the Purchase Agreement.

 

(k)              
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided
by law.

 

(l)                
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

(m)            
Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and
shall not be deemed to limit or affect any of the provisions hereof.

 

(n)              
Independent Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several
and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance
of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any
closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Holders are in any way acting in
concert with respect to such obligations or the transactions contemplated by this Agreement. Each Holder shall be entitled to protect
and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for
any other Holder to be joined as an additional party in any proceeding for such purpose.

 

    	17

    	 

    

 

 

********************

 

 

(Signature
Pages Follow)

 

    	18

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Registration Rights Agreement as of the date first written above.

 

	
        INTERLEUKIN GENETICS,
        INC.

         

         

	
        By:    /s/ Kenneth S. Kornman______________________

        Name: Kenneth S. Kornman

        Title: Chief Executive Officer

         

 

	
        PYXIS INNOVATIONS
        INC.

         

         

	
        By:     /s/ Joseph Landstra________________________

        Name: Joseph Landstra

        Title: Assistant Treasurer

         

 

 

	
        DELTA DENTAL PLAN
        OF MICHIGAN, INC.

         

         

	
        By:     /s/ Jonathan Groat                                                           

        Name: Jonathan Groat

        Title: V.P General Counsel

         

 

 

	
        BTIG, LLC

         

         

	
        By:__/s/ K.C. Stone                                                                   

        Name: K.C. Stone

        Title: Managing Director

         

 

 

  

 

[SIGNATURE PAGE OF PURCHASER HOLDERS FOLLOWS]

 

    	 

    	 

    

[SIGNATURE
PAGE OF HOLDERS TO INTERLEUKIN GENETICS RRA]

 

 

Name of Holder: See Schedule I to the Common Stock Purchase
Agreement, dated May 17, 2013, filed as Exhibit 10.1 to the Current Report on Form 8-K filed by Interleukin Genetics, Inc. on May
20, 2013 (File No. 001-32715).

 

Signature of Authorized Signatory of Holder: __________________________

 

Name of Authorized Signatory: _________________________

 

Title of Authorized Signatory: __________________________

			

 

 

[SIGNATURE PAGES CONTINUE]

 

    	 

    	 

    

Annex A

 

Plan of Distribution

 

Each Selling Stockholder
(the “Selling Stockholders”) of the shares of common stock and any of their pledgees, assignees and successors-in-interest
may, from time to time, sell any or all of their shares of common stock covered hereby on the OTCQB or any other stock exchange,
market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated
prices. A Selling Stockholder may use any one or more of the following methods when selling shares:

 

		·	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		·	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the
block as principal to facilitate the transaction;

 

		·	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		·	an exchange distribution in accordance with the rules of the applicable exchange;

 

		·	privately negotiated transactions;

 

		·	settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a
part;

 

		·	in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such shares at
a stipulated price per share;

 

		·	through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

		·	a combination of any such methods of sale; or

 

		·	any other method permitted pursuant to applicable law.

 

The Selling Stockholders
may also sell shares under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), if
available, rather than under this prospectus.

 

Broker-dealers engaged
by the Selling Stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction
a markup or markdown in compliance with FINRA IM-2440.

 

    	 

    	 

    

 

 

In connection with
the sale of shares of Common Stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of shares of common stock in the course of hedging the
positions they assume. The Selling Stockholders may also sell shares of common stock short and deliver these securities to close
out their short positions, or loan or pledge the shares of common stock to broker-dealers that in turn may sell these securities.
The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or
create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

The Selling Stockholders
and any broker-dealers or agents that are involved in selling the shares may be deemed to be “underwriters” within
the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the shares of common stock. In no event shall any broker-dealer
receive fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).

 

The Company is required
to pay certain fees and expenses incurred by the Company incident to the registration of the shares. The Company has agreed to
indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities
Act.

 

Because Selling Stockholders
may be deemed to be “underwriters” within the meaning of the Securities Act, they will be subject to the prospectus
delivery requirements of the Securities Act including Rule 172 thereunder. The Selling Stockholders have advised us that there
is no underwriter or coordinating broker acting in connection with the proposed sale of the resale shares by the Selling Stockholders.

 

We agreed to keep this
prospectus effective until the earlier of (i) the date on which the shares may be resold by the Selling Stockholders without registration
and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to
be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect
or (ii) all of the shares have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of
similar effect. The resale shares will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale of shares of common stock covered hereby may not be sold unless
they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and is complied with.

 

    	2

    	 

    

 

 

Under applicable rules
and regulations under the Exchange Act, any person engaged in the distribution of the resale shares may not simultaneously engage
in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of
the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and
sales of shares of common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available
to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior
to the time of the sale (including by compliance with Rule 172 under the Securities Act).

 

    	3

    	 

    

Annex B

 

INTERLEUKIN
GENETICS, INC..

 

Selling Stockholder Notice and Questionnaire

 

The
undersigned beneficial owner of shares of common stock (the “Registrable Securities”) of Interleukin Genetics,
Inc., a company organized under the laws of the State of Delaware (the “Company”),
understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”)
a registration statement (the “Registration Statement”) for the registration and resale under Rule 415 of the
Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with
the terms of the Registration Rights Agreement (the “Registration Rights Agreement”) to which this document
is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below.
All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

 

Certain legal consequences
arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders
and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The undersigned beneficial
owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable Securities
owned by it in the Registration Statement.

 

    	 

    	 

    

The undersigned hereby provides the following
information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

		1.	Name.

 

		(a)	Full Legal Name of Selling Stockholder

 

	 	 
	 	 

 

		(b)	Full Legal Name of Registered Holder (if not the same
as (a) above) through which Registrable Securities are held:

 

	 	 
	 	 

 

		(c)	Full Legal Name of Natural Control Person (which means
a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this
Questionnaire):

 

	 	 
	 	 

 

 

2. Address for Notices to Selling
Stockholder:

 

	 	 
	 	 
	 	 

 

	Telephone:	 

	Fax:	 

	email:	 

	Contact Person:	 

 

3. Broker-Dealer Status:

 

		(a)	Are you a broker-dealer?

 

Yes     ̈ No     ̈

 

		(b)	If “yes” to Section 3(a), did you receive
your Registrable Securities as compensation for investment banking services to the Company?

 

Yes     ̈ No     ̈

 

 

 

    	2

    	 

    

  

Note:If
“no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in
the Registration Statement.

 

		(c)	Are you an affiliate of a broker-dealer?

 

Yes     ̈ No     ̈

 

		(d)	If you are an affiliate of a broker-dealer, do you
certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the
Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute
the Registrable Securities?

 

Yes     ̈ No     ̈

 

Note:If
“no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in
the Registration Statement.

 

4. Beneficial Ownership of Securities
of the Company Owned by the Selling Stockholder.

 

Except as set forth below
in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities
issuable pursuant to the Purchase Agreement.

 

		(a)	Type and Amount of other securities beneficially owned
by the Selling Stockholder:

 

	 	 
	 	 
	 	 

  

    	3

    	 

    

5. Relationships with the Company:

 

Except as set forth below,
neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the
equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company
(or its predecessors or affiliates) during the past three years.

 

			State any exceptions here:

 

	 	 
	 	 
	 	 

 

 

The undersigned agrees
to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof at any time while the Registration Statement remains effective.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through
5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements
thereto. The undersigned understands that such information will be relied upon by the Company in
connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements
thereto.

 

IN WITNESS WHEREOF
the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person
or by its duly authorized agent.

 

	Date: 	 	 	Beneficial Owner: 	 

 

	 	 	 	By:	 
	 	 	 	 	
        Name:

        Title:

 

 

PLEASE FAX A COPY (OR EMAIL A .PDF COPY)
OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]